Is heart rate in fish a sensitive indicator to evaluate acute effects of β-blockers in surface water?

2006 ◽  
Vol 22 (3) ◽  
pp. 338-340 ◽  
Author(s):  
D.G. Joakim Larsson ◽  
Stina Fredriksson ◽  
Erik Sandblom ◽  
Nicklas Paxeus ◽  
Michael Axelsson
Keyword(s):  
Heart Rate ◽  
Surface Water ◽  
Sensitive Indicator ◽  
Acute Effects ◽  
Β Blockers

Use of β-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: Are we on target?

2009 ◽  
Vol 158 (3) ◽  
pp. 378-385 ◽  
Author(s):  
Michael Herman ◽  
Jennifer Donovan ◽  
Maichi Tran ◽  
Brigid McKenna ◽  
Joel M. Gore ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Acute Coronary Syndromes ◽  
Coronary Syndromes ◽  
Β Blockers

Cardiac autonomic associations on exercise and ambulatory capacity in individuals with lower-extremity artery disease

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
I Roque Marcal ◽  
N Cornelis ◽  
R Buys ◽  
I Fourneau ◽  
EG Ciolac ◽  
...  
Keyword(s):  
Heart Rate ◽  
Autonomic Function ◽  
Cardiopulmonary Exercise Test ◽  
Treadmill Test ◽  
Cardiopulmonary Exercise ◽  
Sympathetic Modulation ◽  
Β Blocker ◽  
Β Blockers ◽  
Artery Disease ◽  
Lower Extremity Artery Disease

Abstract Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): This work was in part supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP #2019/19596-7), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #303399/2018-0). OnBehalf Exercise and Chronic Disease Research Laboratory - Bauru, Brazil; Research Group for Cardiovascular Rehabilitation - Leuven, Belgium. INTRODUCTION Lower-extremity artery disease (LEAD) characterized by progressive atherosclerotic build-up in leg arteries is becoming increasingly prevalent, affecting more than 200 million people worldwide. In line with other atherosclerotic disorders, LEAD is often associated with autonomic dysfunction as evidenced by a reduced heart rate variability (HRV). To date, little is known on the impact of cardiac autonomic function on exercise and ambulatory capacity. PURPOSE We aimed to investigate whether autonomic function is associated with ambulatory capacity and exercise capacity in patients with LEAD. METHODS Thirty-four patients (age≥17 years) diagnosed with LEAD (ankle brachial index: ABI ≤ 0.9 and/or 20% decrease after a maximal treadmill test) suffering from intermittent claudication (Rutherford I-III) were recruited in the PROSECO-IC trial. Patients were grouped based on beta-blocker medication (β-blocker and non β-blocker). Intervals between R waves (i-RR) obtained by heart rate (HR) signal were acquired beat-to-beat via a digital telemetry system (Polar®️ H10) during 15 min of supine rest and were used for 5-minute HRV analysis. Time domain indexes (mean i-RR, SNDD, pNN50%), and frequency domains (high frequency band (HF), low frequency (LF, very LF (VLF)) and the ratio (LF/HF). HRV was analyzed in absolute (abs), normalized (nu) and log units (log). Ambulatory capacity was assessed by means of a submaximal treadmill test, graded maximal treadmill test using Gardner protocol (GTM) and 6 minutes walking test (6MWT); exercise capacity was assessed by means of a graded maximal cardiopulmonary exercise test (HR, blood pressure (BP) and peak oxygen uptake (VO2peak)) at resting, 2 minutes, and peak of exercise. RESULTS Pearson test showed that sympathetic modulation indexes were moderate associated with pain free distance in GTM (LF/HF: r = 0.52, p = 0.04), and pain free time in 6MWT (LFlog: r=-0.62, p = 0.01; VLF: r=-0.52, p = 0.04), respectively, in patients without β-blocker. Similar HR associations with HRV (time and frequency domain) were observed during submaximal treadmill test and cardiopulmonary exercise test (p ≤ 0.05). Test-t demonstrated a significantly increased response intra-groups in HR and BP during both tests (p ≤ 0.05). Average BP were positive associated with the earlier stages of the cardiopulmonary test (resting to 2 min) with LFlog (r = 0.70, p= <0.001) in β-blocker while non-β-blocker were associated from 2 min to peak with LFabs (r = 0.67, p= <0.001) and LF/HF (r = 0.52, p = 0.03).  CONCLUSION Sympathetic modulation was correlated with a longer pain free walking capacity in non-β-blockers. Yet, individuals treated by -β-blockers showed an earlier sympathetic modulation through exercise pressor response during the first stages of cardiopulmonary exercise compared to non-β-blockers with LEAD.

New Formula to Predict Heart Rate at Anaerobic Threshold That Considers the Effects of β-Blockers in Patients With Myocardial Infarction

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Shinji Nemoto ◽  
Yusuke Kasahara ◽  
Kazuhiro P. Izawa ◽  
Satoshi Watanabe ◽  
Kazuya Yoshizawa ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Rate ◽  
Anaerobic Threshold ◽  
Β Blockers ◽  
New Formula

Acute Effects of Elevation Training Mask on Heart Rate Variability in Healthy Subjects

2017 ◽  
Vol 49 (5S) ◽  
pp. 905
Author(s):  
Hyun Chul Jung ◽  
Nan Hee Lee ◽  
Soeun Jeon ◽  
John D. Smith ◽  
Michael Maspero ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Healthy Subjects ◽  
Acute Effects

scholarly journals Acute Effects of Salvia Supplementation on Cognitive Function in Athletes During a Fatiguing Cycling Exercise: A Randomized Cross-Over, Placebo-Controlled, and Double-Blind Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Nicolas Babault ◽  
Ahmad Noureddine ◽  
Nicolas Amiez ◽  
Damien Guillemet ◽  
Carole Cometti
Keyword(s):  
Heart Rate ◽  
Reaction Time ◽  
Cognitive Function ◽  
Stroop Task ◽  
Perceived Exertion ◽  
Digit Span ◽  
Acute Effects ◽  
Warm Up ◽  
Positive Effects ◽  
Fatiguing Exercise

Background:Salvia (sage) supplementation has been shown to improve the cognition function in healthy individuals or patients (e.g., attention, memory). To date, no study has explored its relevancy in the context of sporting performance. The aim of this study was to explore the acute effects of a combination of Salvia officinalis and Salvia lavandulaefolia on cognitive function in athletes performing a fatiguing cycling task.Methods: Twenty-six volunteers were included in this cross-over, randomized, double-bind vs. placebo trial. Two hours before the two experimental sessions (here called SAGE and PLACEBO), volunteers randomly received a supplementation of sage or placebo. During each experimental session, participants were tested at four occasions while cycling during a warm-up, in the middle and at the end of a fatiguing task and after a short 5-min recovery. Tests included a Stroop task, a simple reaction time task, and a backward digit span memory task. Heart rate and rating of perceived exertion (RPE) were also measured at the beginning of the four test sessions.Results: Heart rate was significantly greater during the fatiguing exercise than during warm-up and recovery (P < 0.001) without any supplementation effect. RPE was greater during the fatiguing exercise than during warm-up and recovery (P < 0.001). Moreover, RPE was significantly lower during the SAGE session as compared to PLACEBO (P = 0.002). Reaction time was not altered during the exercise but was significantly shorter with SAGE as compared to PLACEBO (P = 0.023). The Stroop task only revealed significantly longer reaction time during warm-up as compared to recovery (P = 0.02) independently of the supplementation. The digit span memory test revealed a significant greater span score with SAGE as compared to PLACEBO (P = 0.044).Conclusion: The combination of Salvia improved the cognitive functions (perceived exertion, working memory, and reaction time). The positive effects were obtained in fresh condition and were maintained with fatigue.

Resting heart rate and the use of β-blockers in the treatment of patients with arterial hypertension

2021 ◽  
Vol 14 (1) ◽  
pp. 18-26
Author(s):  
Martyna Waliczek ◽  
Piotr Rozentryt
Keyword(s):  
Heart Rate ◽  
Risk Factor ◽  
Careful Examination ◽  
Resting Heart Rate ◽  
Scientific Societies ◽  
Uncomplicated Hypertension ◽  
Β Blockers ◽  
Standard Risk ◽  
Worse Prognosis ◽  
Elevated Heart Rate

Higher resting heart rate was shown to correlate with worse prognosis both in general population and in various disease groups. Scientific societies dealing with patients with hypertension propose assessment of resting heart rate as a standard risk factor. In patients with uncomplicated hypertension and elevated resting heart rate they propose use of cardioselective β1-adrenolytics. This decision should be preceded by careful examination of potential modified reasons. In the paper we express several concerns regarding standard provision of heart rate lowering drugs in particular clinical situations. The algorithm showing proposed steps in assessment of elevated heart rate is provided.

scholarly journals Acute effects of flexible pole exercise on heart rate dynamics

2015 ◽  
Vol 34 (1) ◽  
pp. 35-42
Author(s):  
Letícia Santana de Oliveira ◽  
Patrícia S. Moreira ◽  
Ana M. Antonio ◽  
Marco A. Cardoso ◽  
Luiz Carlos de Abreu ◽  
...  
Keyword(s):  
Heart Rate ◽  
Acute Effects ◽  
Heart Rate Dynamics

scholarly journals β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry

2020 ◽  
Vol 5 (1) ◽  
pp. 1-10
Author(s):  
Torfinn Eriksen-Volnes ◽  
Arne Westheim ◽  
Lars Gullestad ◽  
Eva Kjøl Slind ◽  
Morten Grundtvig
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Ejection Fraction ◽  
Sinus Rhythm ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Categorical Variables ◽  
Target Dose ◽  
Β Blocker ◽  
Β Blockers

Background: Use of β-blockers and titration to the highest tolerated dose are highly recommended by the European Society of Cardiology (ESC) guidelines for treatment of chronic heart failure (HF) with a reduced ejection fraction (HFrEF), but little attention has been paid to the achieved heart rate (HR) during this treatment. Objectives: The aim of the present study was to examine the achieved HR in relation to the use of β-blockers in these patients. Methods: All of the patients (n = 2,689) in the National Norwegian Heart Failure Registry as part of the Norwegian Cardiovascular Disease Registry with a sinus rhythm and left ventricular ejection fraction (LVEF) <40% at stable follow-up visiting specialised hospital outpatient HF clinics in Norway were included. The β-blocker doses were calculated as a percent of the target dose according to ESC HF guidelines. Differences between baseline variables according to the achieved HR were analysed by the Student’s t test for continuous variables and Pearson’s χ2 test for categorical variables. Linear regression was used to determine the predictors of HR ≥70 beats/min (bpm) in the multivariate analysis. Results: One third of the patients had a resting HR ≥70 bpm. Of the patients with an HR ≥70 bpm, 72.3% used less than the target dose of β-blocker; they were younger and had a higher NYHA class, more diabetes mellitus and chronic obstructive pulmonary disease (COPD), and higher N-terminal pro-B type natriuretic peptide (NT-proBNP) levels and estimated glomerular filtration rates compared to the patients with an HR <70 bpm. The 1-year mortality was 3.1, 3.7, 5.8, and 9.1% among the patients with an HR <70, 70–79, 80–89, and >89 bpm, respectively. Only 2 patients used ivabradine. Conclusions: In patients with HFrEF and sinus rhythm, an HR ≥70 bpm was associated with worse clinical variables and outcomes. A high proportion of the patients who had an HR ≥70 bpm was not treated with or/did not tolerate the target dose of a β-blocker, although the β-blocker dose was higher than in patients with an HR <70 bpm. This may suggest that increased efforts should be made to further increase the β-blocker dose, and treatment with ivabradine could be considered among patients with an HR ≥70 bpm.

Sign in / Sign up

Export Citation Format

Share Document